Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of the 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states, representing 72% of its marketplace membership, was lower than expected [3]. - The company adjusted its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 8, 2025 in Centene Corporation Lawsuit – CNC